Patent classifications
C07K14/805
Preservative solution for heme protein, and method for stabilizing heme protein
An object of the present invention is to provide a novel preservative solution for a heme protein and a method for stabilizing a heme protein, which are effective against denaturation or degradation of a heme protein, and the present invention specifically relates to a preservative solution for a heme protein comprising a disulfonic acid or a salt thereof, and a method for stabilizing a heme protein, which involves bringing a disulfonic acid or a salt thereof into coexistence in a sample comprising a heme protein.
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof. Specific forms of these fusion proteins have the ability to form into spherical nanoparticles possessing a therapeutically agent at their core. This provides a unique basis for employing elastin-like polypeptides as hemoglobin carriers in the manufacture of blood substitutes.
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof. Specific forms of these fusion proteins have the ability to form into spherical nanoparticles possessing a therapeutically agent at their core. This provides a unique basis for employing elastin-like polypeptides as hemoglobin carriers in the manufacture of blood substitutes.
Method for producing n-acetyl-d-glucosamine and/or d-glucosamine salt by microbial fermentation
The present invention discloses a process for producing N-acetyl-D-glucosamine and D-glucosamine salts by microbial fermentation. The invention includes a method to produce N-acetyl-D-glucosamine and/or D-glucosamine salts with higher efficiency and higher yield by increasing the effect of N-acetyl-D-aminomannose-6-phosphate epimerase in microorganisms.
HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
Methods and compositions for producing hemoglobin and treating alpha-thalassemia are disclosed.
COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
Methods and compositions for producing hemoglobin and treating alpha-thalassemia are disclosed.
COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.
COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.